We use cookies on this website. By using the website you accept our use of cookies. Accept

News Archive

 

Novo increases stake in SYNLAB

Novo increases stake in SYNLAB

Munich / Hellerup, 12 April 2017 – SYNLAB Limited (“SYNLAB” or “the Group”), a European market leader for laboratory diagnostics, and Novo A/S (“Novo”), the holding company for the Novo Group and fully owned subsidiary of the Novo Nordisk Foundation, today jointly announce that Novo has agreed to increase its equity stake in the Group through a €250m subscription to new shares. Following the closing of the transaction which is scheduled to take place today, Novo will own a stake of approximately 20% of the equity of SYNLAB.

Read the full press release here.

Luk

Lars Rebien Sørensen elected to the Board of...

Lars Rebien Sørensen elected to the Board of Directors of Novo A/S

Lars Rebien Sørensen

For 16 years, Lars Rebien Sørensen was President and CEO of Novo Nordisk A/S, a leading global pharmaceutical company with a focus on diabetes care. With Lars Rebien Sørensen at the helm, the company’s annual results increased markedly, and in 2016 the company produced its best results ever. Harvard Business Review ranked Lars Rebien Sørensen as the world’s top-performing CEO in 2015 and 2016.

Read the full press release here.

Luk

Novo A/S announces the proposed acquisition of...

Novo A/S announces the proposed acquisition of a 19.95% shareholding in ConvaTec Group Plc

Novo A/S announces the proposed acquisition of a 19.95% shareholding in ConvaTec Group Plc, a UK listed global medical products and technologies company with leading market positions in advanced wound care, ostomy care, continence and critical care and infusion devices. At completion of the transaction, Kasim Kutay, CEO of Novo A/S, will join the Board of Directors of ConvaTec Group Plc. 

Click here to read the press release.

Luk

Jesper Ahlmann Funding Andersen Appointed New...

Jesper Ahlmann Funding Andersen Appointed New President & CEO of Sonion as of April 1st, 2017

Sonion today announced the appointment of Jesper Ahlmann Funding Andersen as the President & CEO of the Sonion Group. Jesper replaces Jørn Mørkeberg Nielsen who was President & CEO of Sonion until the end of 2016.

Click here to read Sonion's news release.

Luk

Novo A/S investerede rekordstort beløb på 8,7...

Novo A/S investerede rekordstort beløb på 8,7 mia. kr. inden for life-science i 2016

Novo A/S, holdingselskabet i Novo Gruppen, øgede sine nye investeringer i life-science- virksomheder fra 3,2 mia. kr. i 2015 til 8,7 mia. kr. i 2016. Novo A/S foretog investeringerne som del af en strategi, der har til formål at styrke selskabets position som en internationalt førende life-science-investor.

Klik her for at læse pressemeddelelsen.

Luk

Novo invests a record DKK 8.7 billion in life...

Novo invests a record DKK 8.7 billion in life sciences in 2016

Novo A/S, the holding company of the Novo Group, increased its new investments in life science companies from DKK 3.2 billion in 2015 to DKK 8.7 billion in 2016 as part of a strategy to strengthen the position of Novo A/S as a leading international life science investor.

Click here to read the press release.

Luk

Video with Kasim Kutay, CEO, Novo A/S

Video with Kasim Kutay, CEO, Novo A/S

Click here to see the video with Kasim Kutay's introduction of Novo A/S.

Luk

ORPHAZYME RAISES EUR 14 MILLION TO FURTHER...

ORPHAZYME RAISES EUR 14 MILLION TO FURTHER EXPAND ITS CLINICAL DEVELOPMENT PROGRAMME

Copenhagen March 9, 2017
 
Orphazyme ApS today announced the successful completion of a EUR 14M financing round. Two new investors, LSP and the ALS Investment Fund joins the investor syndicate comprising Kurma Partners, Idinvest Partners, Novo A/S, Sunstone Capital and Aescap Venture.

Click here to read Orphazyme's news release.
 

Luk

Novo A/S invests in new fund focusing on...

Novo A/S invests in new fund focusing on industrial biotech

Novo A/S, the holding company in the Novo Group, has invested millions of euros in a new international fund: Sofinnova Industrial Biotech 1 (Sofinnova IB-1). The fund will invest in start-ups, venture, and corporate spin-out companies within industrial biotech in the United States and Europe.

Click here to read the press release.

Luk

Inogen Announces Fourth Quarter and Full Year...

Inogen Announces Fourth Quarter and Full Year 2016 Financial Results and Updates 2017

Guidance Company Release - 2/28/2017 4:05 PM ET

- Q4 2016 Sales Revenue up 47.2% Over the Same Period in 2015 -
- Q4 2016 Net Income up 36.3% Over the Same Period in 2015 -
- Q4 2016 Adjusted Net Income up 85.0% Over the Same Period in 2015 -
- Record Revenue for Full Year 2016 -
- Raises 2017 Guidance -

Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three-month and twelve-month periods ended December 31, 2016.

Click here to read Inogen's press release.

Luk

Orexo commences patent infringement litigation...

Orexo commences patent infringement litigation against Actavis for their generic versions of Suboxone® and Subutex® tablets in the US

Click here to read Orexo's press release.

Luk

ACACIA PHARMA ANNOUNCES POSITIVE RESULTS FROM...

ACACIA PHARMA ANNOUNCES POSITIVE RESULTS FROM ITS FOURTH AND FINAL PIVOTAL TRIAL OF BAREMSIS™ FOR THE RESCUE TREATMENT OF PONV

Extensive Phase 3 programme demonstrates clinical potential of BAREMSIS in rescue treatment and prophylaxis of PONV – NDA to be submitted to the US FDA 1H 2017

Cambridge, UK – 13th February 2017

Acacia Pharma Group Ltd (“Acacia Pharma”), the supportive care company developing products for US and international markets, announces positive results from its fourth and final pivotal Phase 3 study investigating BAREMSIS™ (amisulpride injection, formerly APD421) for the rescue treatment of patients who develop post-operative nausea & vomiting (PONV), despite having received prior antiemetic prophylaxis. 

Please click here to read the full press release from Acacia.
 

Luk

ERT Recognized for Improving and Accelerating...

ERT Recognized for Improving and Accelerating Clinical Research

February 16, 2017

Company Named Finalist for PACT Technology Company of the Year Award

ERT, a global data and technology company that minimizes risk and uncertainty in clinical trials, today announced it has been named a finalist for the Philadelphia Alliance for Capital and Technologies (PACT) Technology Company of the Year Award. ERT is one of only three companies nominated to receive this recognition.

Click here to read ERT's news release.
 

Luk

BTG and Society of Interventional Oncology to...

BTG and Society of Interventional Oncology to explore role of minimally invasive therapies in immuno-oncology

15 February 2017

London, UK: BTG plc (LSE: BTG), the global specialist healthcare company, today announced a collaboration with the Society of Interventional Oncology (SIO), a global organization working to nurture and support interventional oncology worldwide, to explore the role of interventional oncology alongside immuno-oncology.

Click here to read BTG's press release.

Luk

Novo A/S becomes new long-term strategic...

Novo A/S becomes new long-term strategic shareholder in Evotec

Please see here for more information.

Luk

Lysogene receives Orphan Drug Designation from...

Lysogene receives Orphan Drug Designation from FDA for LYS-GM101 for treatment of GM1 Gangliosidosis

Click here to read Lysogene's press release.

Luk

Chr. Hansen Holding A/S - Major shareholder...

Chr. Hansen Holding A/S - Major shareholder announcement from BlackRock, Inc.

Hoersholm, 2017-02-01 15:43 CET (GLOBE NEWSWIRE) -- 

Click here to read Chr. Hansen's company announcement no. 4/2017.

Luk

Lilly and CoLucid Pharmaceuticals Announce...

Lilly and CoLucid Pharmaceuticals Announce Agreement for Lilly To Acquire CoLucid

$960 million deal will enhance Lilly’s existing pain management portfolio for migraine; adds potential near-term launch to its late-stage pipeline

INDIANAPOLIS, IN and CAMBRIDGE, MA, January 18, 2017–

Eli Lilly and Company (NYSE: LLY) and CoLucid Pharmaceuticals, Inc. (Nasdaq: CLCD) today announced an agreement for Lilly to acquire CoLucid for $46.50 per share or approximately $960 million. This all-cash transaction will enhance Lilly’s existing portfolio in pain management for migraine, while adding a potential near-term launch to its late-stage pipeline.

Click here to read CoLucid's news release.

Luk

Chr. Hansen - Q1 Results: A good start to the...

Chr. Hansen - Q1 Results: A good start to the year

Chr. Hansen has had a good start to the year with strong organic revenue growth of 11% in Q1 2016/17, which is better than initially expected for the quarter. Revenue reached EUR 242 million – 13% above last year.

Click here to read the full press release.
 

Luk

First Pulmonary Embolism Patients in Hong Kong...

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® system

10 January 2017

BTG plc (LSE: BTG), the global specialist healthcare company, today announced the first patients diagnosed with Pulmonary Embolism (PE) to be treated in Hong Kong using the newly available EKOS® system. The EKOS® system includes an ultrasonic device that uses acoustic pulses to quickly and safely dissolve blood clots and restore blood flow in patients with PE, deep vein thrombosis (DVT), and peripheral arterial occlusions (PAO).

Click here to read the full news release from BTG.
 

Luk

Pages